International Stem Cell Corp. (OTCQB: ISCO) builds
shareholder value through the development of restorative medicine using stem
cell technology. Through its innovative parthenogenesis technology, the company
makes use of human stem cells from unfertilized oocytes (eggs), bypassing
common ethical controversy that accompanies the destruction of the viable human
embryo. Additionally, the company works with subsidiaries Lifeline Skin
Technology and Lifeline Skin Care in the area of skin rejuvenation on a product
that contains a nano-compound that facilitates the replenishment of the skin’s
texture and elasticity.
Evidence of the company’s resolve to be a leader in the
field of restorative medicine can be found in a recent partnership with The
Florey Institute of Neuroscience and Mental Health, one of the world’s leading
brain research centers. The agreement calls for the team to launch Phase I/IIa
clinical trials research on the effects of human parthenogenetic stem cells in
people with Parkinson’s disease.
The credibility The Florey Institute brings to ISCO’s
mission to build shareholder value cannot be understated. The Florey Institute
of Neuroscience and Mental Health is one of the world’s leading brain research
centers, employing a staff of over 500. The center’s scientists comprise the
largest neuroscience research team in Australia. Its work is conducted on a
range of serious diseases, including stroke, epilepsy, Alzheimer’s disease,
Parkinson’s disease, traumatic brain and spinal cord injury, depression, multiple
sclerosis, Huntington’s disease, motor neuron disease, schizophrenia, mental
illness and addiction. Further, The Florey is viewed by many as a world leader
in imaging technology, stroke rehabilitation and epidemiological studies.
The company’s human cell culture products are made up of
adult stem cells and reagents for regenerative medicine aiding in the study of
prostate disease, human renal and bladder diseases, human corneal cells present
in corneal disease and other cell culture reagents and supplements for the
growth, staining, and freezing of human cells. ISCO markets and sells skincare
products through its website, channel sales, distributors and human cell
culture products through its sales force, OEM partners, and brand distributors.
International Stem Cell Corp. was founded in 2001 and is headquartered in
Carlsbad, California.
For more information, visit www.internationalstemcell.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
